TG Therapeutics (TGTX) Upgraded to “Hold” at ValuEngine

ValuEngine upgraded shares of TG Therapeutics (NASDAQ:TGTX) from a sell rating to a hold rating in a research note published on Wednesday.

Several other analysts also recently commented on TGTX. BidaskClub downgraded shares of TG Therapeutics from a sell rating to a strong sell rating in a research report on Friday, July 20th. Zacks Investment Research raised shares of TG Therapeutics from a sell rating to a hold rating in a research report on Thursday, July 26th. HC Wainwright restated a buy rating and set a $38.00 target price on shares of TG Therapeutics in a research note on Tuesday, August 7th. Raymond James cut shares of TG Therapeutics from a strong-buy rating to an outperform rating and lowered their target price for the company from $22.00 to $12.00 in a research note on Tuesday, September 25th. Finally, LADENBURG THALM/SH SH set a $27.00 target price on shares of TG Therapeutics and gave the company a buy rating in a research note on Wednesday, September 26th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $26.00.

TGTX stock traded down $0.11 during trading on Wednesday, hitting $4.86. 1,122,070 shares of the stock traded hands, compared to its average volume of 1,597,473. TG Therapeutics has a 1 year low of $4.80 and a 1 year high of $17.35.



TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). TG Therapeutics had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. On average, analysts forecast that TG Therapeutics will post -2.15 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp lifted its stake in TG Therapeutics by 19.3% during the 2nd quarter. Northern Trust Corp now owns 751,725 shares of the biopharmaceutical company’s stock valued at $9,885,000 after acquiring an additional 121,424 shares during the period. Bank of New York Mellon Corp lifted its stake in TG Therapeutics by 11.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 276,325 shares of the biopharmaceutical company’s stock valued at $3,633,000 after acquiring an additional 29,012 shares during the period. Millennium Management LLC lifted its stake in TG Therapeutics by 34.8% during the 2nd quarter. Millennium Management LLC now owns 525,552 shares of the biopharmaceutical company’s stock valued at $6,911,000 after acquiring an additional 135,562 shares during the period. MetLife Investment Advisors LLC lifted its stake in TG Therapeutics by 35.2% during the 2nd quarter. MetLife Investment Advisors LLC now owns 28,284 shares of the biopharmaceutical company’s stock valued at $372,000 after acquiring an additional 7,358 shares during the period. Finally, RA Capital Management LLC lifted its stake in TG Therapeutics by 73.1% during the 2nd quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock valued at $56,266,000 after acquiring an additional 1,806,452 shares during the period. Institutional investors and hedge funds own 48.98% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Read More: Buyback

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply